BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 19387579)

  • 1. Preparation of sustained release microparticles with improved initial release property.
    Jung GY; Na YE; Park MS; Park CS; Myung PK
    Arch Pharm Res; 2009 Mar; 32(3):359-65. PubMed ID: 19387579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel powder formulations for controlled delivery of poorly soluble anticancer drug: application and investigation of TPGS and PEG in spray-dried particulate system.
    Mu L; Teo MM; Ning HZ; Tan CS; Feng SS
    J Control Release; 2005 Apr; 103(3):565-75. PubMed ID: 15820404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Doxorubicin-loaded star-shaped copolymer PLGA-vitamin E TPGS nanoparticles for lung cancer therapy.
    Zhang J; Tao W; Chen Y; Chang D; Wang T; Zhang X; Mei L; Zeng X; Huang L
    J Mater Sci Mater Med; 2015 Apr; 26(4):165. PubMed ID: 25791459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of formulation parameters on 2-methoxyestradiol release from injectable cylindrical poly(DL-lactide-co-glycolide) implants.
    Desai KG; Mallery SR; Schwendeman SP
    Eur J Pharm Biopharm; 2008 Sep; 70(1):187-98. PubMed ID: 18472254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Poly(lactide)-vitamin E derivative/montmorillonite nanoparticle formulations for the oral delivery of Docetaxel.
    Feng SS; Mei L; Anitha P; Gan CW; Zhou W
    Biomaterials; 2009 Jul; 30(19):3297-306. PubMed ID: 19299012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vitamin E TPGS-emulsified poly(lactic-co-glycolic acid) nanoparticles for cardiovascular restenosis treatment.
    Feng SS; Zeng W; Teng Lim Y; Zhao L; Yin Win K; Oakley R; Hin Teoh S; Hang Lee RC; Pan S
    Nanomedicine (Lond); 2007 Jun; 2(3):333-44. PubMed ID: 17716178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preparation, characterization and in vitro cytotoxicity of indomethacin-loaded PLLA/PLGA microparticles using supercritical CO2 technique.
    Kang Y; Wu J; Yin G; Huang Z; Yao Y; Liao X; Chen A; Pu X; Liao L
    Eur J Pharm Biopharm; 2008 Sep; 70(1):85-97. PubMed ID: 18495445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alpha-tocopheryl polyethylene glycol succinate-emulsified poly(lactic-co-glycolic acid) nanoparticles for reversal of multidrug resistance in vitro.
    Wang Y; Guo M; Lu Y; Ding LY; Ron WT; Liu YQ; Song FF; Yu SQ
    Nanotechnology; 2012 Dec; 23(49):495103. PubMed ID: 23149859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel oleanolic acid-loaded PLGA-TPGS nanoparticle for liver cancer treatment.
    Bao X; Gao M; Xu H; Liu KX; Zhang CH; Jiang N; Chu QC; Guan X; Tian Y
    Drug Dev Ind Pharm; 2015; 41(7):1193-203. PubMed ID: 25026246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanoparticles of poly(lactide)/vitamin E TPGS copolymer for cancer chemotherapy: synthesis, formulation, characterization and in vitro drug release.
    Zhang Z; Feng SS
    Biomaterials; 2006 Jan; 27(2):262-70. PubMed ID: 16024075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Water-free microencapsulation of proteins within PLGA microparticles by spray drying using PEG-assisted protein solubilization technique in organic solvent.
    Mok H; Park TG
    Eur J Pharm Biopharm; 2008 Sep; 70(1):137-44. PubMed ID: 18515053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Docetaxel-loaded nanoparticles based on star-shaped mannitol-core PLGA-TPGS diblock copolymer for breast cancer therapy.
    Tao W; Zeng X; Liu T; Wang Z; Xiong Q; Ouyang C; Huang L; Mei L
    Acta Biomater; 2013 Nov; 9(11):8910-20. PubMed ID: 23816645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction in burst release after coating poly(D,L-lactide-co-glycolide) (PLGA) microparticles with a drug-free PLGA layer.
    Ahmed AR; Elkharraz K; Irfan M; Bodmeier R
    Pharm Dev Technol; 2012; 17(1):66-72. PubMed ID: 20854130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Silicon microfluidic flow focusing devices for the production of size-controlled PLGA based drug loaded microparticles.
    Keohane K; Brennan D; Galvin P; Griffin BT
    Int J Pharm; 2014 Jun; 467(1-2):60-9. PubMed ID: 24680950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unintended potential impact of perfect sink conditions on PLGA degradation in microparticles.
    Klose D; Delplace C; Siepmann J
    Int J Pharm; 2011 Feb; 404(1-2):75-82. PubMed ID: 21056644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro and in vivo studies on vitamin E TPGS-emulsified poly(D,L-lactic-co-glycolic acid) nanoparticles for paclitaxel formulation.
    Win KY; Feng SS
    Biomaterials; 2006 Apr; 27(10):2285-91. PubMed ID: 16313953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Folate-decorated poly(lactide-co-glycolide)-vitamin E TPGS nanoparticles for targeted drug delivery.
    Zhang Z; Huey Lee S; Feng SS
    Biomaterials; 2007 Apr; 28(10):1889-99. PubMed ID: 17197019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel controlled release formulation for the anticancer drug paclitaxel (Taxol): PLGA nanoparticles containing vitamin E TPGS.
    Mu L; Feng SS
    J Control Release; 2003 Jan; 86(1):33-48. PubMed ID: 12490371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TPGS-g-PLGA/Pluronic F68 mixed micelles for tanshinone IIA delivery in cancer therapy.
    Zhang J; Li Y; Fang X; Zhou D; Wang Y; Chen M
    Int J Pharm; 2014 Dec; 476(1-2):185-98. PubMed ID: 25223472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Water-soluble betamethasone-loaded poly(lactide-co-glycolide) hollow microparticles as a sustained release dosage form.
    Chaw CS; Yang YY; Lim IJ; Phan TT
    J Microencapsul; 2003; 20(3):349-59. PubMed ID: 12881115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.